Christine Zhou started her career as a physician and clocked nearly two decades at drugmaker Eli Lilly before joining rival Novo Nordisk in 2018, where she is now president for the China region. China ...
Novo Nordisk and Mylan Pharmaceuticals, now part of Viatris, have settled their patent dispute over Novo’s blockbuster ...
Novo Nordisk and Viatris have agreed to resolve a patent dispute over Novo's blockbuster weight-loss drugs Ozempic and Wegovy ...
Natco Pharma shares rise 3% as partner Mylan settles U.S. patent litigation with Novo Nordisk for generic Ozempic.
Pfizer ( PFE 3.18%) stock jumped 3.1% through 11:20 a.m. ET Monday morning in response to a Wall Street Journal article over ...
Novo Nordisk plans to invest approximately $158 million into revamping its Montes Claros manufacturing facility in Minas Gerais, Brazil, Bloomberg reported Oct. 5.
A $13 million grant from Golden LEAF Foundation will fund training equipment at Wilson Community College to support Johnson & ...
With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...
Bristol Myers Squibb's schizophrenia drug, which received FDA approval last week, took a long and winding road to get there. Three decades ago, Eli Lilly developed the drug's forerunner, xanomeline, ...
Plus, pension funds renew attack on London Stock Exchange, new “titans of Wall Street” Jane Street under the microscope and ...
Novo Nordisk says Massachusetts plays a key role in its bid to expand beyond its historic focus as a diabetes and obesity ...
NATCO Pharma Ltd announced that Mylan Pharmaceuticals Inc has settled a lawsuit with Novo Nordisk in the US concerning the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback